Physician profile
Muneer E Assi
NPI 1598721904
$7,071.27
in general payments reported to CMS, 2019-2025
44 companies · $801 in 2025
The $801 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $1,517 · 2021: $1,290 · 2022: $889 · 2023: $742 · 2024: $536 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $725.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $654.80 | 2019-2022 | |
| Abbvie INC. | $557.32 | 2019-2025 | Ubrelvy |
| Novo Nordisk INC | $514.41 | 2019-2024 | Ozempic |
| Janssen Pharmaceuticals, INC | $493.98 | 2019-2022 | |
| Pfizer INC. | $473.48 | 2020-2025 | |
| Amgen INC. | $395.12 | 2019-2025 | Evenity, Otezla, Repatha |
| Astellas Pharma US INC | $265.98 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $240.41 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $230.50 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.96 | 2020-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $212.74 | 2021-2023 | |
| Abbott Laboratories | $204.30 | 2022-2025 | Freestyle Libre 3 |
| Eisai INC. | $164.76 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.59 | 2020-2025 | Xifaxan |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muneer Assi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.